Crossmark

Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells

Crossref DOI link: https://doi.org/10.1136/jitc-2024-009604

Published Online: 2024-12-02

Published Print: 2024-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Park, Daniel H https://orcid.org/0000-0002-2773-320X
Bhojnagarwala, Pratik S https://orcid.org/0000-0002-9403-5276
Liaw, Kevin

Bordoloi, Devivasha

Tursi, Nicholas J

Zhao, Shushu

Binder, Zev A

O’Rourke, Donald

Weiner, David B
Funding

Funding for this research was provided by:

W.W. Smith Charitable Trust (SG2201)

INOVIO Pharmaceuticals (SRA21-4)
License Information

License valid from 2024-11-19

Document is current

Any future updates will be listed below